Respiratory Syncytial Articles & Analysis
6 articles found
The rapid accelerated fibrosarcoma/mitogen-activated protein kinase kinase/extracellular signal-regulated kinase (Raf/MEK/ERK) signaling pathway represents one of those targets for broad-spectrum antiviral drug development as it is exploited by many viruses during their replication cycle, e.g., coronaviruses, Ebola virus, hepatitis C virus, respiratory syncytial ...
In addition to the three diseases mentioned above, there are a large number of vaccines against respiratory syncytial virus in development (31), with recent breakthroughs in targeting stable pre-F proteins, two recombinant protein vaccines PF-06928316 and GSK3844766A producing >80% protection in Phase III trials. ...
As an EPA-registered disinfectant with proven efficacy against the norovirus, SteraMist also offers the results and material capability that allows for daily defense against other illnesses that peak during the winter months, including Respiratory Syncytial Virus (RSV) and more. Not only does SteraMist feature efficacy against norovirus but getting rid of it has ...
The rise in prevalence of viral respiratory infections in humans and increase in health care expenditure are projected to boost the growth of the global respiratory antiviral treatment market. Respiratory syncytial virus, influenza virus, parainfluenza virus, adenovirus, rhinovirus, and coronavirus belong to the ...
Summary The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic began in 2019 and rapidly scaled to a global presence of disease known as COVID-19. ...
These viruses cause brain inflammation and respiratory symptoms. People infected with either of these diseases have a 50% to 100% chance of dying. ...